Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The goal of this intervention clinical trial is to learn about the protection of isomaltooligosaccharides (IMO) on intestinal bacterial translocation in patients with liver cirrhosis. The main question is to answer the changes of LPS after adminstration of IMO.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Administration of IMO | Experimental | Patients will be given IMO (20g/100ml) for 7 days. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Isomaltooligosaccharides (IMO) | Dietary Supplement | Patients will still receive standard treatment, including medicine and other invasive treatment. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Changes of Lipopolysaccharide (LPS) in plasma | LPS will be tested by Tachypiens Amebocyte Lysate (TAL) test | Before (Day-0) and after treatment (Day-8). |
| Measure | Description | Time Frame |
|---|---|---|
| Changes of bacterial load in plasma | Count the Colony-Forming Units (CFU) to value the bacterial load | Before (Day-0) ,after treatment (Day-8), after 7-day non-treatment (day 15). |
| Changes of markers of infections (CRP) in plasma |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Jinjun Chen, PhD | Contact | 44-13902246336 | chjj@smu.edu.cn |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Nanfang Hospital | Recruiting | Guangzhou | Guangdong | China |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Acutely decompensated cirrhosis ( with ascites).
Not provided
Not provided
Not provided
Not provided
C-reactive protein
| Before (Day-0) ,after treatment (Day-8), after 7-day non-treatment (day 15). |
| Changes of markers of infections (PCT) in plasma | Procalcitonin，PCT | Before (Day-0) ,after treatment (Day-8), after 7-day non-treatment (day 15). |
| Changes of markers of kidney failure (Cr) in plasma | Creatinine，Cr | Before (Day-0) ,after treatment (Day-8), after 7-day non-treatment (day 15). |
| Changes of markers of coagulation failure (INR) in plasma | International normalized ratio，INR | Before (Day-0) ,after treatment (Day-8), after 7-day non-treatment (day 15). |
| Changes of markers of liver failure (TBIL) in plasma | Total bilirubin，TBIL | Before (Day-0) ,after treatment (Day-8), after 7-day non-treatment (day 15). |
| Changes of Lipopolysaccharide (LPS) in plasma after 7-day non-treatment | LPS will be tested by Tachypiens Amebocyte Lysate (TAL) test | After 7-day non-treatment (day 15). |
| Incidence of bacterial infection | All kinds of infection, including pneumonia, SBP, urine tract infection and so on. | After treatment (Day-8) up to follow-up (Day-28) |
| Development of acute-on-chronic liver failure | Diagnosis of ACLF is based on the criteria of EASL-ACLF. | After treatment (Day-8) up to follow-up (Day-28) |
| Changes of Meld scores which evaluate severity of liver diseases. | Model for End-Stage Liver Disease (MELD) is used to estimates a patient's chances of surviving their disease during the next three months. This numerical scale is used for adult patients waiting for a transplant. The MELD score ranges from 6 to 40 (gravely ill). The individual score tells you what is the urgency of undergoing a liver transplant during the next 90 days (three months). | Before (Day-0) ,after treatment (Day-8), after 7-day non-treatment (day 15). |
| 28-day mortality | Day-28 |